

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 428 880 A1**

(12) **EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
16.06.2004 Bulletin 2004/25

(51) Int Cl.7: **C12N 15/12, C12P 21/02,**  
**C07K 14/47, C12Q 1/68**

(21) Application number: **02758863.1**

(86) International application number:  
**PCT/JP2002/008457**

(22) Date of filing: **22.08.2002**

(87) International publication number:  
**WO 2003/027287 (03.04.2003 Gazette 2003/14)**

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**IE IT LI LU MC NL PT SE SK TR**

- **KANAI, Yoshikatsu**  
Hachioji-shi, Tokyo 193-0931 (JP)
- **ENOMOTO, Atsushi**  
Nishio-shi, Aichi 445-0054 (JP)

(30) Priority: **21.09.2001 JP 2001290291**

(71) Applicant: **Human Cell Systems, Inc.**  
**Tokyo 103-0012 (JP)**

(74) Representative: **Cresswell, Thomas Anthony**  
**J.A. KEMP & CO.**  
**14 South Square**  
**Gray's Inn**  
**London WC1R 5JJ (GB)**

(72) Inventors:  
• **ENDO, Hitoshi**  
**Sagamihara-shi, Kanagawa 229-0022 (JP)**

(54) **KIDNEY-SPECIFIC URATE TRANSPORTER AND GENE THEREOF**

(57) It is intended to identify and provide a novel urate transporter gene participating in the urate transport in the kidney and a urate transporter which is a polypeptide encoded by the above gene. Namely, a protein comprising the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence derived

therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting uric acid and its analogs; and a gene encoding this protein.

EP 1 428 880 A1

BEST AVAILABLE COPY

**Description**Technical field

- 5 [0001] The present invention relates to a gene participating in transport of uric acid and analogs thereof or exchange transport of uric acid and the other anion, and a polypeptide encoded by the gene.

Background Art

- 10 [0002] In human race and primates, uric acid which is an organic acid is a final metabolite in purine metabolism in cells, and is excreted mainly from the kidney. In species other than the human race and the primates, it is metabolized to allantoin by an action of uricase in liver, and is excreted from the kidney. Therefore, for the other mammals, it seems that effects of dynamic abnormality of uric acid which is an intermediate product in the kidney on living body are small. Losing the action of uricase in the evolution process seems to be a cause of the fact that the human race has suffered from gout due to hyperuricemia since ancient times.

- 15 [0003] In humans, when is caused the decrease of uric acid excretion in the kidney causes hyperuricemia, the gout develops at high percentage, which becomes a risk factor for cardiovascular diseases and hypertension. On the other hand, it has been known that the increase of uric acid excretion in the kidney causes renal hypouricemia. Although abnormality of uric acid kinetics is not obvious in these diseases, it has been supposed that urate transporters in the kidney are deeply involved.

- 20 [0004] The uric acid kinetics in the kidney has been studied by experimental systems using a removed organ perfusion method and an isolated cell membrane vesicle system. In humans, it has been demonstrated that uric acid freely passes through renal glomerulus and thereafter mechanisms for reabsorption and secretion exist in proximal convoluted tubule. However, by the conventional technique, it has been difficult that urate transport system via cell membrane is analyzed in detail, and it has been desired that the transporter per se is isolated and analyzed.

- 25 [0005] It has been known that there is a remarkable difference among species in the urate transport in the kidney, and there exist the species where secretion is dominant such as swine and rabbit and the species where the reabsorption is dominant such as human, rat and dog. The swine of the species with secretion dominance excretes from 200 to 300% of uric acid per unit nephron, whereas a human of the species with uric acid reabsorption dominance excretes only about 10% of uric acid per unit nephron. Also, it has been known that responses to uricosuric accelerators and uricosuric inhibitors are different even among the species with reabsorption dominance. Accordingly, since the kinetics of uric acid and the responses to drugs in the kidney are different depending on the species, and uric acid is reciprocally transported, it has not been easy to isolate a molecular entity of the urate transporter though its existence has been assumed.

- 30 [0006] Among the urate transporters in the kidney, the transporters which reabsorb uric acid from renal tubular lumen have been studied for long time by the experimental system using the isolated cell membrane vesicle system. For the drugs currently used for the patients with hyperuricemia and gout, it is assumed that the transporter which reabsorbs uric acid in the kidney is inhibited. Also, it is forecasted that renal hypouricemia is caused due to gene aberration of this transporter.

- 40 [0007] Recently, it has been demonstrated that the transporters involved in the reabsorption of uric acid are exchange transporters of uric acid and various anions in several experiments. For pyrazinamide used as the first-line drug of antituberculous drugs at present, it has been shown that pyrazine carboxylate which is the metabolite of pyrazinamide is an exchange substrate of this exchange transporter and facilitates the reabsorption of uric acid. That is thought to be the cause of hyperuricemia frequently observed in the patients administered the antituberculous drug.

- 45 [0008] Accordingly, the transporter involved in the reabsorption of uric acid in the kidney is thought to play an important role for internal kinetics of uric acid. It has been anticipated that elucidation of its molecular entity leads to elucidate a mechanism of action of uricosuric accelerators and a cause of renal hypouricemia, and development of new gout curative medicines.

- 50 [0009] We have previously isolated and reported organic anion transporters, OAT1 (organic anion transporter) (Sekine, T. et al., J. Biol. Chem., 272:18526-18529, 1997), OAT2 (Sekine, T. et al., FEBS Letter, 429:179-182, 1998), OAT3 (Kusuhara, H. et al., J. Biol. Chem., 274:13675-13680, 1999), and OAT4 (Cha, S. H. et al., J. Biol. Chem., 275: 4507-4512, 2000) which play central roles in medicament transport in the kidney, liver, brain, placenta and so on. These transporters belonging to OAT family are the transporters capable of transporting many organic anions with different chemical structures, and also perform the transport of various anionic medicaments.

- 55 [0010] It was not obvious whether the urate transporter belongs to the known transporter family, but since uric acid is a dibasic acid having both pyrimidine structure and imidazole structure and is one of the organic anions, the possibility that the urate transporter phylogenetically belongs to OAT family was anticipated. In OAT family, since OAT4 exists at the side of renal tubular lumen in the kidney and the existence of the transporter involved in the reabsorption of uric

acid is also assumed at the side of renal tubular lumen, it has been also anticipated that the transporter is phylogenetically similar to OAT4.

[0011] From these facts, we have anticipated that the urate transporter in the kidney belongs to the organic ion transporter family.

#### Disclosure of the Invention

[0012] An object of the present invention is to identify and provide a novel urate transporter gene participating in the urate transport in the kidney and a urate transporter which is a polypeptide encoded by the above gene. Other objects will be apparent from the following description.

#### Brief Description of the Drawings

#### [0013]

Figure 1 shows the results of analyzing the expression of URAT1 gene messenger RNA in various organ tissues of human adult and embryo by Northern blotting.

Figure 2 shows the result of time dependency in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 3 shows the result of concentration dependency in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 4 shows the result of examining the effects of added salts in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 5 shows the result of pH dependency in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 6 shows the result of preincubation with various organic acids in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 7 shows the result of examining the effect of previously injected unlabeled lactic acid (100 mM, 10 nl) in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 8 shows the result of examining the effects of addition of various organic acids or analog compounds thereof to the system in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 9 shows the result of examining the effects of probenecid addition at various concentrations to the system in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 10 shows the result of examining the effects of losartan addition at various concentrations to the system in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 11 shows exon-intron structure of URAT1 gene in human genome.

#### Best Mode for Carrying Out the Invention

[0014] As described above, the present inventors isolated four organic anion transporters, OTA1, OTA2, OTA3 and OTA4. They have about 40% homology of amino acid sequences each other. On the basis of these sequences, disclosed information of human genome project was searched, and multiple novel gene fragments having homology to OAT1, 2, 3 and 4 were identified. Among them, one novel gene fragment extremely closed to a gene locus position of OAT4 was analyzed, and a site supposed to be an initiation codon was identified. A primer specific for 5' upstream of this initiation codon was made, and isolation of this novel gene was attempted by 3'-RACE (3-rapid amplification of cDNA ends) method using messenger RNA derived from various tissues of humans. As a result, a novel clone (URAT1) which had been never reported was identified by the 3'-RACE method using human kidney messenger RNA.

[0015] The urate transporter1, URAT1 of the present invention has an ability to transport uric acid and its analogs via cell membrane from one side to the other side and further is a urate/anion exchanger by making the anion at the other side of the cell membrane an exchange substrate.

[0016] The protein of the present invention includes, for example, those having the amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence represented by SEQ ID NO: 1, in addition to one having the amino acid sequence represented by SEQ ID NO:1. The amino acids could be deleted, substituted or added to the extent where urate transport activity is not lost, and typically from 1 to about 110 and preferably from 1 to about 55. Such proteins typically have up to 75% and preferably up to 90% homologous amino acid sequences to the amino acid sequence represented by SEQ ID NO:1.

[0017] In the present invention, the isolation of the gene by the 3'-RACE method can be carried out typically by making a primer of about 30 bases specific for guanine- or cytosine-rich gene at the 5' upstream of the initiation codon,

performing reverse transcription of tissue-derived messenger RNA using an oligo dT primer with an adapter sequence, and subsequently performing PCR (polymerase chain reaction) using the adapter sequence and the gene-specific primer. It is possible to further enhance accuracy of the PCR by the use of heat resistant polymerase with higher fidelity.

[0018] The urate transporter gene of the present invention can be isolated and yielded by screening cDNA library prepared using renal tissues or cells in an appropriate mammal as a gene source. The mammals include human in addition to non-human animals such as dog, cattle, horse, goat, sheep, monkey, swine, rabbit, rat and mouse.

[0019] The screening and isolation of the gene can be suitably carried out by homology screening and PCR method.

[0020] For the resultant cDNA, it is possible to determine the base sequence by the conventional method, analyze the translation region and determine the amino acid sequence of the protein encoded by this, i.e., URAT1.

[0021] It can be verified, for example, by the following method that the obtained gene is cDNA of the urate transporter gene, i.e., a gene product encoded by the cDNA is the urate transporter. The ability to transport (uptake) uric acid into cells can be confirmed by introducing cRNA (complementary RNA) prepared from the obtained URAT1 cDNA into oocyte to express, and measuring the uptake of a substrate into the cells by the conventional uptake experiment using uric acid as the substrate (Sekine, T. et al., *Biochem. Biophys. Res. Commun.*, 251:586-591, 1998).

[0022] Also, transport property and substrate specificity of URAT1 can be examined by applying the similar uptake experiment to expressing cells.

[0023] Further, the property of URAT1, for example, the property that URAT1 performs the transport with time dependency, substrate selectivity and pH dependency of URAT1 can be examined by applying the similar uptake experiment to the expressing cells.

[0024] Homologous genes and chromosomal genes derived from the different tissues or different organisms can be isolated by screening appropriate cDNA libraries or genomic DNA libraries made from the different gene sources using cDNA of the obtained URAT1 gene.

[0025] Also, the gene can be isolated from the cDNA library by the conventional PCR method using synthetic primers designed on the basis of the information of the disclosed base sequence of the gene of the present invention (the base sequence represented by SEQ ID NO:1 or a part thereof).

[0026] The DNA libraries such as cDNA library and genomic DNA library can be prepared by the methods described in, for example, "Sambrook, J., Fritsch E. F., and Maniatis, T., "Molecular Cloning" (published by Cold Spring Harbor Laboratory Press in 1989)". Or when there is a commercially available library, it may be used.

[0027] To obtain the structure of URAT1 gene on human genome, the genomic DNA library is screened using the obtained URAT1 gene cDNA, and the obtained clones are analyzed. Or the structure may be searched on the basis of the disclosed information of the human genome analysis results using a homology search program.

[0028] The urate transporter (URAT1) of the present invention can be produced by gene recombination technology using cDNA which encodes the urate transporter. For example, it is possible to incorporate DNA (cDNA, etc.) which encodes the urate transporter in an appropriate expression vector and introduce the resultant recombinant DNA into appropriate host cells. Expression systems (host vector system) for producing the polypeptide include the expression systems of bacteria, yeast, insect cells and mammalian cells. Among these, to obtain the functional protein, it is desirable to use the insect cells and the mammalian cells.

[0029] For example, when the polypeptide is expressed in the mammalian cells, an expression vector is constructed by inserting DNA which encodes the urate transporter in the downstream of an appropriate promoter (e.g., SV40 promoter, LTR promoter, elongation 1 $\alpha$  promoter and the like) in an appropriate expression vector (e.g., retroviral vector, papilloma virus vector, vaccinia virus vector, SV40 type vector and the like). Next, the target polypeptide is produced by transforming appropriate animal cells with the obtained expression vector and culturing transformants in an appropriate medium. The mammalian cells as the hosts include cell lines such as monkey COS-7 cells, Chinese hamster CHO cells, human HeLa cells and primary culture cells derived from renal tissues, LLC-PK1 cells derived from swine kidney, OK cells derived from opossum kidney, and proximal convoluted tubule S1, S2 and S3 cells derived from mouse.

[0030] As the cDNA which encodes the urate transporter URAT1, it is possible to use the cDNA having the base sequence shown in the sequence 1, and further it is possible to design DNA corresponding to the amino acid sequence and use the DNA which encodes the polypeptide without being limited to the above cDNA. In this case, 1 to 6 codons which encode one amino acid are known, and the codon used may be optionally selected, but it is possible to design the sequence with high expression by considering use frequency of codons in the host utilized for the expression. The DNA with the designed sequence can be acquired by chemical synthesis of DNA, fragmentation and bind of the above cDNA, partial modification of the base sequence and the like. The artificial partial modification and mutagenesis can be carried out by site specific mutagenesis methods (Mark, D. F. et al., *Proc. Natl. Acad. Sci. USA*, 18:5662-5666, 1984) utilizing primers including synthetic oligonucleotides which encode the desired modification.

[0031] The nucleotides (oligonucleotides or polynucleotides) which hybridize with the urate transporter gene of the present invention under a stringent condition can be used as probes to detect the urate transporter gene, and further can be used, for example, as antisense oligonucleotides, ribozymes and decoys to modulate the expression of the urate transporter. As such nucleotides, it is possible to use, for example, the nucleotides typically comprising the partial

sequence of consecutive 14 or more bases or the complementary sequence thereof in the base sequence represented by SEQ ID NO:1. In order to make the hybridization more specific, as the partial sequence, the longer sequence, e.g., the sequence of 20 or more bases or 30 or more bases may be used.

**[0032]** Also, using the urate transporter of the present invention or the polypeptide having immunological equivalence thereto, it is possible to acquire antibodies thereof, and the antibodies can be utilized for the detection and the purification of the urate transporter. The antibody can be produced by using the urate transporter of the invention, a fragment thereof, or a synthetic peptide having the partial sequence thereof and the like as an antigen. The polyclonal antibody can be produced by the conventional method in which the antigen is inoculated to the host animal (e.g., rat or rabbit) and immunized serum is collected, and the monoclonal antibody can be produced by the conventional technology such as a hybridoma method.

**[0033]** Furthermore, the present invention provides a screening method of a substance having uricosuric accelerating action. The protein of the invention works for transporting uric acid into the cells and is deeply involved in the reabsorption of uric acid. Also, as is shown in Figures 6, 8, 9 and 10, it is possible to quantify the accelerating or inhibiting action for uric acid uptake of the screening substance in the system where the protein of the invention is expressed, by adding uric acid to the system, further adding the screening substance thereto, and comparing a uric acid uptake amount with that in the case with no addition of the screening substance. As is shown in Figures 6 and 8, the substances clinically used as uricosuric accelerators have remarkably inhibited the uptake of uric acid in the above experimental system, and thus, it is shown that it become possible to screen the uricosuric accelerating action of the screening substance in this system. As the cells used in this screening system, the cells are not limited to oocytes used in the following experiments, and it is possible to use various living cells as long as the cells can express the protein of the invention.

**[0034]** Therefore, the present invention provides the method for screening substances having uricosuric regulating action using the protein of the invention. As the uricosuric regulating actions, there are the uricosuric accelerating action and the uricosuric inhibiting action, and those having the uricosuric accelerating action are preferable for the treatment/prevention of hyperuricemia and gout. Thus, the preferable uricosuric regulating action includes the uricosuric accelerating action. Moreover, the present invention provides uricosuric regulators screened by the above screening method. The preferable uric acid regulator includes a uricosuric accelerators. The uricosuric regulator screened by the method of the invention can regulate the uptake of uric acid by the urate transporter involved in the urate transport in the kidney, and therefore can be used as an active ingredient of the medicines for the treatment/prevention of various diseases associated with the reabsorption of uric acid such as hyperuricemia and gout.

**[0035]** It is possible to make the obtained active ingredient a pharmaceutical composition using a pharmacologically acceptable carrier.

#### Examples

**[0036]** The present invention is described in more detail by examples below, but these examples do not limit the invention.

**[0037]** In the following examples, unless otherwise specified, respective manipulations were carried out by the methods described in "Sambrook, J., Fritsch E. F., and Maniatis, T., "Molecular Cloning" (published by Cold Spring Harbor Laboratory Press in 1989)" or when using commercially available kits, they were used according to the instructions of the commercially available articles.

#### Example 1 : Isolation of kidney-specific urate transporter (URAT1) cDNA and analysis thereof

**[0038]** On the basis of the base sequence information of OAT1, OAT2, OAT3 and OAT4 already isolated by the present inventors, the disclosed analysis results of the human genome project were searched using the homology search program. As a result, multiple novel gene fragments having homology to OAT1, OAT2, OAT3 and OAT4 were obtained. Among them, one of the novel gene fragments extremely close to the locus position of OAT4 was analyzed, and the site thought to be the initiation codon was identified in it. This initiation codon was identified by comparing the novel gene fragments with gene sequences of OAT1 and OAT4.

**[0039]** A primer specific for the 5' upstream region of the predicted initiation codon was made using 28 bases, and the isolation of this novel gene was attempted by 3'-RACE (3'-rapid amplification of cDNA ends) method using messenger RNA derived from various tissues of human. As a result, a monoclonal (URAT1) was obtained by the 3'-RACE method using human kidney messenger RNA. A single band obtained by PCR method was subcloned in pCRII-TOPO vector using TA cloning method, and further subcloned in pcDNA 3.1 (+) vector which was the expression vector. As a result, a novel cDNA (DRAT1 cDNA) which has urate transport activity was obtained (for analysis of transport function, see the followings.).

**[0040]** Determination of the base sequence of the cDNA (URAT1 cDNA) obtained by the above was carried out

using specific primers by an automatic sequencer (manufactured by Applied Biosystems) (described in SEQ ID NO:1).  
 [0041] The expression of URAT1 gene was analyzed in various tissues of human (Northern blotting) (Figure 1). Full length URAT1 cDNA was labeled with  $^{32}\text{P}$ -dCTP, and using this as a probe, hybridization was carried out using filters (manufactured by Clontech) blotting RNA extracted from various human tissues. The hybridization was carried out overnight in a hybridization solution comprising the labeled full length URAT1 cDNA, and the filters were washed with 0.1xSSC comprising 0.1% SDS at 65°C. As a result of Northern blotting, an intensive band was detected in the renal tissue. In human embryonic tissues, the band was detected in the kidney.

#### Example 2: Analysis of urate transporter functions

[0042] From plasmid comprising URAT1 cDNA, cRNA (RNA complementary to cDNA) was prepared in vitro using T7 RNA polymerase (see Sekine, T., et al., J. Biol. Chem., 272:18526-18529, 1997).

[0043] The resultant cRNA was injected in oocytes of platanna, and uptake experiments of the radiolabeled uric acid in these oocytes were carried out according to the method already reported (Sekine, T., et al., J. Biol. Chem., 272: 18526-18529, 1997). As a result, it was found that the oocytes in which URAT1 was expressed showed uptake of [ $^{14}\text{C}$ ] uric acid as shown in Figure 2. The oocytes in which URAT1 was expressed showed time dependency in the uptake of [ $^{14}\text{C}$ ] uric acid. This indicated that not only URAT1 was bound to uric acid but also was the transporter to transport it into the cells. No uptake of [ $^{14}\text{C}$ ] PAH (para-amino hippuric acid) and [ $^{14}\text{C}$ ] TEA (tetraethylammonium) which are a representative substrate of the organic ion transporter family was observed (not shown).

[0044] Michaelis-Menten dynamic experiment in urate transport by URAT1 was carried out. Concentration dependency of uric acid in the transport by URAT1 was studied by examining change of uptake amounts of uric acid at various concentrations by URAT1. The uptake experiment of the radiolabeled uric acid was carried out using oocytes injected with URAT1 cRNA according to the method described above. As a result (Figure 3),  $K_m$  value (Michaelis constant number) of the uric acid uptake was approximately  $372 \pm 25 \mu\text{M}$ .

[0045] The effect of various electrolytes on the urate transport by URAT1 was studied (Figure 4). When extracellular sodium was replaced with lithium, choline and N-methyl-D-glucamine (NMDG), the urate transport via URAT1 was not changed. It was demonstrated that URAT1 was the extracellular sodium-independent urate transporter. When extracellular potassium ions were completely replaced with sodium (0-K<sup>+</sup> in Figure 4) and sodium was completely replaced with the potassium ions (96 mM KCl), the urate transport was not also changed, which was demonstrated that URAT1 was cell membrane potential-independent. When extracellular chloride ions were replaced with gluconic acid, the uptake of uric acid was significantly increased. From the experimental system using the isolated cell membrane vesicle system, the presence of the exchanger for uric acid and chloride was shown at the side of renal tubular lumen in human kidney. Thus, this experimental result suggests that chloride might be the exchange substrate of uric acid.

[0046] The pH dependency in the urate transport by URAT1 was studied. As shown in Figure 5, when the extracellular pH was acidified, the urate transport in the oocyte injected with URAT1 cRNA was increased, but this seems to be caused by non-specific absorption of uric acid in the oocytes injected with water (control). The substantial urate transport (URAT1-control) was not changed depending on pH.

#### Example 3: Study on exchange substrate of uric acid in the urate transporter

[0047] From the experimental system using the isolated cell membrane vesicle system, it has been suggested that monocarboxylic acids such as lactic acid and nicotinic acid can be the exchange substrate of uric acid in the uric acid/anion exchanger in the human kidney. In order to study the exchange substrate of uric acid in URAT1, the oocytes were preincubated with these monocarboxylic acids (1 mM), para-amino hippuric acid and ketoglutaric acid, and subsequently the transport of uric acid was measured (Figure 6). When the oocytes were preincubated with 1mM of pyrazine carboxylic acid and nicotinic acid (3-pyridine carboxylic acid), the uptake of uric acid was significantly increased in the oocytes injected with URAT1 cRNA. On the other hand, when the oocytes were preincubated with para-amino hippuric acid and ketoglutaric acid which were not monocarboxylic acids, the uptake of uric acid was not facilitated. The above results indicate that monocarboxylic acids such as pyrazine carboxylic acid and nicotinic acid are the exchange substrate of uric acid.

[0048] In Figure 6, when the oocytes were preincubated with lactic acid which was monocarboxylic acid, the uptake of uric acid was not facilitated. It was thought to be occurred because the incorporated lactic acid was transported outside of the cells via a pathway other than URAT1 due to abundant expression of endogenous lactate transporters in the oocytes. Also, it was anticipated that low affinity of lactic acid to URAT1 as shown below was also one of the causes. Therefore, 100 nl of 100 mM non-radiolabeled L-lactic acid was precedently injected in the oocytes, and then the uptake of the radiolabeled uric acid was observed (Figure 7). When lactic acid was precedently injected, the significantly high uptake of uric acid was observed compared to the case where water was injected. Even when para-amino hippuric acid and ketoglutaric acid were injected, no change was observed compared to the case where water

was injected (not shown).

**[0049]** From the results in Figures 6 and 7, URAT1 is the exchanger of uric acid and monocarboxylic acid. Pyrazinamide which is an antituberculous drug is metabolized to become pyrazine carboxylic acid, which is then excreted into urine, whereas it is said to facilitate the reabsorption of uric acid. The above result shows that as a result of the exchange of uric acid and pyrazine carboxylic acid in URAT1, the uptake of uric acid is facilitated. Accordingly the mechanism to cause hyperuricemia has been demonstrated which is a side effect of pyrazinamide which is the antituberculous drug.

#### Example 4: Screening of inhibitory substance for urate transporter

**[0050]** In order to further study substrate selectivity of URAT1, in the uptake experiment system of [<sup>14</sup>C] uric acid by the oocytes injected with URAT1 cRNA, various substances were added to the system and their effects were examined (inhibitory experiments). The uptake experiment of [<sup>14</sup>C] uric acid was carried out using the oocytes injected with URAT1 cRNA according to the method described above (Figures 8, 9 and 10). The uptake of 50 μM [<sup>14</sup>C] uric acid was measured under the condition at pH 7.4 in the presence and absence of various compounds (unlabeled) at the concentrations shown in Figure 8. As a result, various monocarboxylic acids (L-lactic acid, D-lactic acid, nicotinic acid, pyrazine carboxylic acid) significantly inhibited the transport of [<sup>14</sup>C] uric acid by URAT1 (Figure 8). Ketoglutaric acid which was dicarboxylic acid and could be the exchange substrate of OAT1 did not inhibit under the condition at pH 7.4. Pyrazine dicarboxylic acid which had a similar structure to pyrazine carboxylic acid showed slightly weak inhibitory effect. Anionic and cationic substances such as para-amino hippuric acid and tetraethylammonium did not show any inhibitory action (Figure 8).

**[0051]** Medicines used for the treatment of hyperuricemia, such as probenecid, benz-bromarone, sulfinpyrazon and phenylbutazone, significantly inhibited the uptake of uric acid in URAT1. Losartan which is a drug for the treatment of hypertension and has been known to have the uricosuric accelerating action, significantly inhibited the uptake of uric acid by URAT1 as well as its metabolite, EXP-3174. From the above results, URAT1 is an action site of representative uricosuric accelerators clinically used at present.

**[0052]** The inhibitory effects on the uptake action of uric acid via URAT1 were examined using probenecid and losartan at various concentrations (Figures 9 and 10). Their IC<sub>50</sub> values were approximately 50 μM and 20 μM, respectively.

#### Example 5: Structural analysis of URAT1 gene

**[0053]** The structure of URAT1 gene in the human genome was analyzed. The disclosed information of the human genome analysis results was searched using the homology search program, and the exon-intron structure of the URAT1 gene was demonstrated. As shown in Figure 11, the URAT1 gene was consisted of 10 exons and the initiation codon existed in the first exon.

#### Industrial Applicability

**[0054]** The kidney-specific urate transporter which selectively transports uric acid of the present invention and its gene enable to study in vitro the transport of uric acid and its analogs at the site where the transporter is expressed and forecast internal kinetics of the compounds based on the study. Uric acid is the factor deeply involved in hyperuricemia and gout, and it appears that the invention of the transporter will contribute the elucidation of pathogenesis of hyperuricemia and gout in future. The transporter has the action to reabsorb uric acid in the kidney, and it appears that the transporter will contribute the elucidation of causative gene of renal hypouricemia where reabsorption mechanism of uric acid is lost. Additionally, the elucidation of novel compounds inhibiting the function of the transporter and control factors modulating the expression can contribute the development of new therapeutic methods for hyperuricemia and gout.

## SEQUENCE LISTING

5 <110> ENDOU, Hitoshi

10 <120> kidnial specific urate transporter and gene thereof

15 <130> JA921603

20 <150> JP 2001-290291

<151> 2001-09-21

25 <160> 2

30 <170> PatentIn Ver. 2.1

<210> 1

35 <211> 2642

<212> DNA

40 <213> Homo sapiens

<220>

45 <221> CDS

<222> (148)..(1809)

50 <400> 1

gccccgagtc tglgaagcct agccgctggg clggagaagc cacigtgggc accaccgtgg 60



gggaaacagg cccgllgccc tggcctcllt gccctgggcc agcclllgig aagtgggccc 120

ctcltclggg ccccllgagt agglacc atg gca tll tcl gaa ctc clg gac ctc 174

Met Ala Phe Ser Glu Leu Leu Asp Leu

glg ggl ggc clg ggc agg ttc cag gll ctc cag acg atg gct clg atg 222

Val Gly Gly Leu Gly Arg Phe Gln Val Leu Gln Thr Met Ala Leu Met

10 15 20 25

glc tcc atc atg tgg clg tgt acc cag agc atg clg gag aac ttc tgc 270

Val Ser Ile Met Trp Leu Cys Thr Gln Ser Met Leu Glu Asn Phe Ser

30 35 40

gcc gcc glg ccc agc cac cgc tgc tgg gca ccc ctc clg gac aac agc 318

Ala Ala Val Pro Ser His Arg Cys Trp Ala Pro Leu Leu Asp Asn Ser

45 50 55

acg gcl cag gcc agc atc cta ggg agc ttg agt cct gag gcc ctc clg 366

Thr Ala Gln Ala Ser Ile Leu Gly Ser Leu Ser Pro Glu Ala Leu Leu

60 65 70

gcl att tcc atc ccc ccg ggc ccc aac cag agg ccc cal cag tgc cgc 414

Ala Ile Ser Ile Pro Pro Gly Pro Asn Gln Arg Pro His Gln Cys Arg

75 80 85

cgc ttc cgc cag cca cag tgg cag ctc ttg gac ccc aat gcc acg gcc 462

Arg Phe Arg Gln Pro Gln Trp Gln Leu Leu Asp Pro Asn Ala Thr Ala

90 95 100 105

EP 1 428 880 A1

acc agc tgg agc gag gcc gac acg gag ccg tgt gtg gal ggc tgg gtc 510  
 5 Thr Ser Trp Ser Glu Ala Asp Thr Glu Pro Cys Val Asp Gly Trp Val  
 110 115 120

10 tat gac cgc agc atc ttc acc tcc aca atc gtg gcc aag tgg aac ctc 558  
 Tyr Asp Arg Ser Ile Phe Thr Ser Thr Ile Val Ala Lys Trp Asn Leu  
 125 130 135

15 gtg tgt gac tct cac gct ctg aag ccc atg gcc cag tcc atc tac ctg 606  
 20 Val Cys Asp Ser His Ala Leu Lys Pro Met Ala Gln Ser Ile Tyr Leu  
 140 145 150

25 gct ggg att ctg gtg gga gct gct gcg tgc ggc cct gcc tca gac agg 654  
 Ala Gly Ile Leu Val Gly Ala Ala Ala Cys Gly Pro Ala Ser Asp Arg  
 30 155 160 165

35 ttt ggg cgc agg ctg gtg cta acc tgg agc tac ctt cag atg gct gtg 702  
 Phe Gly Arg Arg Leu Val Leu Thr Trp Ser Tyr Leu Gln Met Ala Val  
 170 175 180 185

40 atg ggt acg gca gct gcc ttc gcc cct gcc ttc ccc gtg tac tgc ctg 750  
 Met Gly Thr Ala Ala Ala Phe Ala Pro Ala Phe Pro Val Tyr Cys Leu  
 45 190 195 200

50 ttc cgc ttc ctg ttg gcc ttt gcc gtg gca ggc glc atg atg aac acg 798  
 Phe Arg Phe Leu Leu Ala Phe Ala Val Ala Gly Val Met Met Asn Thr  
 55 205 210 215

EP 1 428 880 A1

5      ggc act ctc ctg atg gag tgg acg gcg gca cgg gcc cga ccc ttg gtg      846  
      Gly Thr Leu Leu Met Glu Trp Thr Ala Ala Arg Ala Arg Pro Leu Val  
          220                      225                      230

10      atg acc ttg aac tct ctg ggc ttc agc ttc ggc cat ggc ctg aca gct      894  
      Met Thr Leu Asn Ser Leu Gly Phe Ser Phe Gly His Gly Leu Thr Ala  
          235                      240                      245

15      gca gtg gcc tac ggt gtg cgg gac tgg aca ctg ctg cag ctg gtg gtc      942  
      Ala Val Ala Tyr Gly Val Arg Asp Trp Thr Leu Leu Gln Leu Val Val  
          250                      255                      260                      265

20      tgg gtc ccc ttc ttc ctc tgc ttt ttg tac tcc tgg tgg ctg gca gag      990  
      Ser Val Pro Phe Phe Leu Cys Phe Leu Tyr Ser Trp Trp Leu Ala Glu  
          270                      275                      280

25      tgg gca cga tgg ctc ctc acc aca ggc agg ctg gat tgg ggc ctg cag      1038  
      Ser Ala Arg Trp Leu Leu Thr Thr Gly Arg Leu Asp Trp Gly Leu Gln  
          285                      290                      295

30      gag ctg tgg agg gtg gct gcc atc aac gga aag ggg gca gtg cag gac      1086  
      Glu Leu Trp Arg Val Ala Ala Ile Asn Gly Lys Gly Ala Val Gln Asp  
          300                      305                      310

35      acc ctg acc cct gag gtc ttg ctt tca gcc atg cgg gag gag ctg agc      1134  
      Thr Leu Thr Pro Glu Val Leu Leu Ser Ala Met Arg Glu Glu Leu Ser  
          315                      320                      325

40      atg ggc cag cct cct gcc agc ctg ggc acc ctg ctc cgc atg ccc gga      1182

Met Gly Gln Pro Pro Ala Ser Leu Gly Thr Leu Leu Arg Met Pro Gly  
 330 335 340 345  
 5  
 ctg cgc ttc cgg acc tgt atc tcc acg ttg tgc tgg ttc gcc ttt ggc 1230  
 10 Leu Arg Phe Arg Thr Cys Ile Ser Thr Leu Cys Trp Phe Ala Phe Gly  
 350 355 360  
 15  
 ttc acc ttc ttc ggc ctg gcc ctg gac ctg cag gcc ctg ggc agc aac 1278  
 Phe Thr Phe Phe Gly Leu Ala Leu Asp Leu Gln Ala Leu Gly Ser Asn  
 20 365 370 375  
 atc ttc ctg ctc caa atg ttc att ggt gtc gtg gac atc cca gcc aag 1326  
 25 Ile Phe Leu Leu Gln Met Phe Ile Gly Val Val Asp Ile Pro Ala Lys  
 380 385 390  
 30  
 atg ggc gcc ctg ctg ctg ctg agc cac ctg ggc cgc cgc ccc acg ctg 1374  
 Met Gly Ala Leu Leu Leu Leu Ser His Leu Gly Arg Arg Pro Thr Leu  
 35 395 400 405  
 gcc gca tcc ctg ttg ctg gcg ggg ctc tgc att ctg gcc aac acg ctg 1422  
 40 Ala Ala Ser Leu Leu Leu Ala Gly Leu Cys Ile Leu Ala Asn Thr Leu  
 410 415 420 425  
 45  
 gtg ccc cac gaa atg ggg gct ctg cgc tca gcc ttg gcc gtg ctg ggg 1470  
 Val Pro His Glu Met Gly Ala Leu Arg Ser Ala Leu Ala Val Leu Gly  
 50 430 435 440  
 ctg ggc ggg gtg ggg gct gcc ttc acc tgc atc acc atc tac agc agc 1518  
 55 Leu Gly Gly Val Gly Ala Ala Phe Thr Cys Ile Thr Ile Tyr Ser Ser

445                      450                      455  
 5                      gag ctc ttc ccc act gtc ctc agg atg acg gca gtc ggc ttg ggc cag 1566  
                     Glu Leu Phe Pro Thr Val Leu Arg Met Thr Ala Val Gly Leu Gly Gln  
 10                      460                      465                      470  
 15                      atg gca gcc cgt gga gga gcc atc ctg ggc cct ctg gtc cgg ctg ctg 1614  
                     Met Ala Ala Arg Gly Gly Ala Ile Leu Gly Pro Leu Val Arg Leu Leu  
 20                      475                      480                      485  
 25                      ggt gtc cat ggc ccc tgg ctg ccc ttg ctg gtc tat ggc acg gtc cca 1662  
                     Gly Val His Gly Pro Trp Leu Pro Leu Leu Val Tyr Gly Thr Val Pro  
 30                      490                      495                      500                      505  
 35                      gtc ctg agt ggc ctg gcc gca ctg ctt ctg ccc gag acc cag agc ttg 1710  
                     Val Leu Ser Gly Leu Ala Ala Leu Leu Leu Pro Glu Thr Gln Ser Leu  
 40                      510                      515                      520  
 45                      ccg ctg ccc gac acc atc caa gat gtc cag aac cag gca gta aag aag 1758  
                     Pro Leu Pro Asp Thr Ile Gln Asp Val Gln Asn Gln Ala Val Lys Lys  
 50                      525                      530                      535  
 55                      gca aca cat ggc acg ctg ggc aac tct gtc cta aaa tcc aca cag ttt 1806  
                     Ala Thr His Gly Thr Leu Gly Asn Ser Val Leu Lys Ser Thr Gln Phe  
 60                      540                      545                      550  
 65                      tag cct cct gagg aacc tgc gat ggg acg gtc gag gaagaga ctt ctt ctt 1859

1 tctciggaga aggcaggagg aaagcaaaga cctccatttc cagaggcca gaggcigccc 1919  
 5 tctgaggicc ccactciccc ccagggcigc cctccaggc gagccctgcc ccctcacag 1979  
 10 tccaaggggc ccccttcaat actgaagggg aaaaggacag ttgatiggc aggaggtagc 2039  
 15 ccagtcacc atcacccigc cctgcccicg tggcttcgga gagcagaggc gtcaggccca 2099  
 20 gggaacgag ctggccctgc caacctcig ctgactccg cactgccact tgcctccca 2159  
 25 cacccticca cctgcccaga gctcagagc aaccaccaic caiggicaag acccticcta 2219  
 30 gctccacaca agcagtagag tctcagctcc acagctttac ccagaagccc tctaagccig 2279  
 35 gcccctggcc cctccccaig tccctccagg cctcagccac ctgcccacca cactctcigc 2339  
 40 ctgctgiccc ctcccccacc tcatccctga cctgctccac ttaaccccca aaccagccc 2399  
 45 cctctccagg ggctcagggc cagccctaga tggccctgaa actcttacc acagttacag 2459  
 50 ccataagcct gccctciccc accctgccag cctatgagtt cccagagggt tggggcagtc 2519  
 55 ccatgacccc atgtccagc tccccacaca gcgcctggcc agagaggcat tggctcgagg 2579  
 gatigaataa agaaacaaat gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2639  
 aaa 2642

&lt;210&gt; 2

&lt;211&gt; 553

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Ala Phe Ser Glu Leu Leu Asp Leu Val Gly Gly Leu Gly Arg Phe

1

5

10

15

Gln Val Leu Gln Thr Met Ala Leu Met Val Ser Ile Met Trp Leu Cys

20

25

30

Thr Gln Ser Met Leu Glu Asn Phe Ser Ala Ala Val Pro Ser His Arg

35

40

45

Cys Trp Ala Pro Leu Leu Asp Asn Ser Thr Ala Gln Ala Ser Ile Leu

50

55

60

Gly Ser Leu Ser Pro Gln Ala Leu Leu Ala Ile Ser Ile Pro Pro Gly

65

70

75

80

Pro Asn Gln Arg Pro His Gln Cys Arg Arg Phe Arg Gln Pro Gln Trp

85

90

95

Gln Leu Leu Asp Pro Asn Ala Thr Ala Thr Ser Trp Ser Glu Ala Asp

100

105

110

Thr Glu Pro Cys Val Asp Gly Trp Val Tyr Asp Arg Ser Ile Phe Thr

115

120

125

Ser Thr Ile Val Ala Lys Trp Asn Leu Val Cys Asp Ser His Ala Leu

130

135

140

Lys Pro Met Ala Gln Ser Ile Tyr Leu Ala Gly Ile Leu Val Gly Ala

145

150

155

160

Ala Ala Cys Gly Pro Ala Ser Asp Arg Phe Gly Arg Arg Leu Val Leu

165

170

175

Thr Trp Ser Tyr Leu Gln Met Ala Val Met Gly Thr Ala Ala Ala Phe

	180	185	190
5	Ala Pro Ala Phe Pro Val Tyr Cys Leu Phe Arg Phe Leu Leu Ala Phe		
	195	200	205
10	Ala Val Ala Gly Val Met Met Asn Thr Gly Thr Leu Leu Met Glu Trp		
	210	215	220
15	Thr Ala Ala Arg Ala Arg Pro Leu Val Met Thr Leu Asn Ser Leu Gly		
	225	230	235 240
20	Phe Ser Phe Gly His Gly Leu Thr Ala Ala Val Ala Tyr Gly Val Arg		
	245	250	255
25	Asp Trp Thr Leu Leu Gln Leu Val Val Ser Val Pro Phe Phe Leu Cys		
	260	265	270
30	Phe Leu Tyr Ser Trp Trp Leu Ala Glu Ser Ala Arg Trp Leu Leu Thr		
	275	280	285
35	Thr Gly Arg Leu Asp Trp Gly Leu Gln Glu Leu Trp Arg Val Ala Ala		
	290	295	300
40	Ile Asn Gly Lys Gly Ala Val Gln Asp Thr Leu Thr Pro Glu Val Leu		
	305	310	315 320
45	Leu Ser Ala Met Arg Glu Glu Leu Ser Met Gly Gln Pro Pro Ala Ser		
	325	330	335
50	Leu Gly Thr Leu Leu Arg Met Pro Gly Leu Arg Phe Arg Thr Cys Ile		
	340	345	350
55	Ser Thr Leu Cys Trp Phe Ala Phe Gly Phe Thr Phe Phe Gly Leu Ala		
	355	360	365
60	Leu Asp Leu Gln Ala Leu Gly Ser Asn Ile Phe Leu Leu Gln Met Phe		
	370	375	380
65	Ile Gly Val Val Asp Ile Pro Ala Lys Met Gly Ala Leu Leu Leu Leu		
	385	390	395 400
70	Ser His Leu Gly Arg Arg Pro Thr Leu Ala Ala Ser Leu Leu Leu Ala		
	405	410	415



Gly Leu Cys Ile Leu Ala Asn Thr Leu Val Pro His Glu Met Gly Ala  
 420 425 430  
 Leu Arg Ser Ala Leu Ala Val Leu Gly Leu Gly Gly Val Gly Ala Ala  
 435 440 445  
 Phe Thr Cys Ile Thr Ile Tyr Ser Ser Glu Leu Phe Pro Thr Val Leu  
 450 455 460  
 Arg Met Thr Ala Val Gly Leu Gly Gln Met Ala Ala Arg Gly Gly Ala  
 465 470 475 480  
 Ile Leu Gly Pro Leu Val Arg Leu Leu Gly Val His Gly Pro Trp Leu  
 485 490 495  
 Pro Leu Leu Val Tyr Gly Thr Val Pro Val Leu Ser Gly Leu Ala Ala  
 500 505 510  
 Leu Leu Leu Pro Glu Thr Gln Ser Leu Pro Leu Pro Asp Thr Ile Gln  
 515 520 525  
 Asp Val Gln Asn Gln Ala Val Lys Lys Ala Thr His Gly Thr Leu Gly  
 530 535 540  
 Asn Ser Val Leu Lys Ser Thr Gln Phe  
 545 550

#### Claims

1. A protein comprising the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting uric acid and its analogs.
2. The protein according to claim 1 which is derived from human.
3. The protein according to claim 1 or 2 which is derived from organs, tissues or cultured cells.
4. A gene encoding the protein according to claim 1.
5. DNA comprising the base sequence represented by SEQ ID NO:1 or DNA hybridizing with the DNA under a stringent condition and encoding a protein being capable of transporting uric acid and its analogs or exchanging uric acid and the other anion.
6. The gene according to claim 5, which is derived from human.

7. The gene according to claim 5 or 6, which is derived from organs, tissues or cultured cells.
8. The gene according to any of claims 4 to 7 or a plasmid comprising a gene encoding a protein of the gene.
- 5 9. The plasmid according to claim 8, wherein the plasmid is an expression plasmid.
10. Host cells transformed with the plasmid according to claim 8 or 9.
- 10 11. Nucleotides comprising a partial sequence of consecutive 14 bases or more in the base sequence represented by SEQ ID NO:1 or a complementary sequence thereof.
12. The nucleotides according to claim 11, used as a probe to detect the gene encoding the protein being capable of transporting uric acid and its analogs or exchanging uric acid and other anion.
- 15 13. The nucleotides according to claim 11, used to modulate the expression of the gene encoding the protein being capable of transporting uric acid and its analogs or exchanging uric acid and other anion.
14. An antibody against the protein according to any of claims 1 to 3.
- 20 15. A method for detecting an action of a subject substance as a substrate for an ability to transport uric acid of the protein and its analogs or exchange uric acid and other anion using the protein according to any of claims 1 to 3.
16. A method for screening substances having a uricosuric regulating action using the protein according to any of claims 1 to 3.
- 25 17. A uricosuric regulating agent capable of being screened by the method according to claim 16.
18. A method for changing kinetics of uric acid and its analogs transported by the protein in the kidney, by modulating an ability to transport uric acid of the protein and its analogs or exchange the uric acid and other anion, using the protein according to any of claims 1 to 3, a specific antibody thereof, a function accelerating substance thereof or a function inhibiting substance thereof.
- 30 19. A method for changing effects of uric acid and its analogs transported by the protein on kinetics in the kidney, by modulating an ability to transport uric acid of the protein and its analogs or exchange the uric acid and other anion, using the protein according to any of claims 1 to 3, a specific antibody thereof, a function accelerating substance thereof or a function inhibiting substance thereof.
- 35 20. A method for changing effects of uric acid and its analogs transported by the protein on total blood concentrations, by modulating an ability to transport uric acid of the protein and its analogs or exchange the uric acid and other anions, using the protein according to any of claims 1 to 3, a specific antibody thereof, a function accelerating substance thereof or a function inhibiting substance thereof.
- 40 21. A method for detecting and changing effects of uric acid and its analogs transported by the protein on kinetics in the kidney, by excessively expressing the protein in the certain cells or by modulating an ability to transport uric acid of the protein existing in the cells and its analogs, using the protein according to any of claims 1 to 3, a specific antibody thereof, a function accelerating substance thereof or a function inhibiting substance thereof, and cDNA (complementary DNA) encoding the same.
- 45
- 50
- 55

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6






FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11

## EXON-INTRON ORGANIZATION OF URAT1 GENE

EXON			INTRON			EXON		
No.	SIZE(bp)	3' BINDING SITE	5' BINDING SITE	SIZE(bp)	No.	3' BINDING SITE	5' BINDING SITE	No.
1	586	...GTGGCCAAG	GTAGGGCCT...	819	1	...TCCCATCAG	TGGAACCTC...	2
2	104	...CTCAGACAG	GTGAGTACC...	521	2	...GTGCCGCAG	GTITGGGCG...	3
3	155	...GCACTCTCC	GTAGGTCTC...	74	3	...TCCTTGCAG	TGATGGAGT...	4
4	169	...GTACTCTCG	GTGGGTGCT...	4247	4	...CCACTTAAG	GTGGCTGGC...	5
5	124	...ACCCCTGAG	GTAAGGCTG...	167	5	...CCTCCACAG	GTCTTGCTT...	6
6	116	...GTTGTGCTG	GTAGATGCC...	751	6	...CTGCCCCAG	GTTCGCCCT...	7
7	215	...TGCCCCACG	GTGAGGGGG...	475	7	...TACCCACAG	AAATGGGGG...	8
8	109	...TGTTGCTCAG	GTGAGGCTG...	258	8	...CAITGGCAG	GATGACGGC...	9
9	204	...GCAGAACCA	GTGAGTGA...	548	9	...CCTGAACAG	GGCAGTAAA...	10
10	857	...ACAAATGAA						

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/08457

## A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl<sup>7</sup> C12N15/12, C12P21/02, C07K14/47, C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl<sup>7</sup> C12N15/00-C12N15/12, C12P21/00-C12P21/02

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

JICST FILE (JOIS), SwissProt/PIR/GeneSeq,  
Genbank/EMBL/DBJ/GeneSeq, BIOSIS (DIALOG)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Michael S. LIPKOWITZ et al., Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. The Journal of Clinical Investigation, June 2001, Vol.107, No.9, pages 1103 to 1115	1-16, 18-21
A	JoAnne E. RACE et al., Molecular Cloning and Characterization of Two Novel Human Renal Organic Anion Transporters (hOAT1 and hOAT3). Biochemical and Biophysical Research Communications, 1999, Vol.255, No.2, pages 508 to 514	1-16, 18-21
X	NIH-MGC, 602107541F1 NC1 CGAP Kid14 Mus musculus c DNA clone IMAGE:4235795 5', mRNA sequence., GeneBank, 21 January, 2001 (21.01.01), BF782700	11

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search  
01 November, 2002 (01.11.02)Date of mailing of the international search report  
03 December, 2002 (03.12.02)Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/08457

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 17  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Although the "urate discharge controller" described in Claim 17 is specified by a screening method, no specific substance obtained by the screening method is described. Therefore, it is unknown what substances are involved therein. Thus, this claim is described in an extremely unclear manner.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**